This is a working overview of glucagon receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-07 and is reviewed periodically as new material appears.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
For polymeric nanoparticles, the induction of stimuli-responsiveness has usually relied heavily upon well-known polymers that possess an inherent stimuli-responsiveness. Certain polymers that can undergo reversible phase transitions due to changes in temperature or pH have aroused interest. Arguably the most utilized polymer for activation-modulated delivery is the thermo-responsive polymer poly(N-isopropylacrylamide). It is readily soluble in water at room temperature but precipitates reversibly from when the temperature is raised above its lower critical solution temperature (LCST), changing from an extended chain conformation to a collapsed chain. This feature presents a way to change the hydrophilicity of a polymer via temperature. Efforts also focus on dual stimuli-responsive drug delivery systems, which can be harnessed to control the release of the encapsulated drug. For example, the triblock copolymer of poly(ethylene glycol)-b-poly(3-aminopropyl-methacrylamide)-b-poly(N-isopropylacrylamide) (PEG-b-PAPMA-b-PNIPAm) can self-assemble to form micelles, possessing a core–shell–corona architecture above the lower critical solution temperature. It is also pH responsive. Therefore, drug release can be tuned by changing either temperature or pH conditions.
== Formal scientific review == In 2006, the U.S. National Academy of Sciences released the report of a study of molecular manufacturing (not molecular assemblers per se) as part of a longer report, A Matter of Size: Triennial Review of the National Nanotechnology Initiative The study committee reviewed the technical content of Nanosystems, and in its conclusion states that no current theoretical analysis can be considered definitive regarding several questions of potential system performance, and that optimal paths for implementing high-performance systems cannot be predicted with confidence. It recommends funding for experimental research to produce experimental demonstrations in this area: "Although theoretical calculations can be made today, the eventually attainable range of chemical reaction cycles, error rates, speed of operation, and thermodynamic efficiencies of such bottom-up manufacturing systems cannot be reliably predicted at this time. Thus, the eventually attainable perfection and complexity of manufactured products, while they can be calculated in theory, cannot be predicted with confidence. Finally, the optimum research paths that might lead to systems which greatly exceed the thermodynamic efficiencies and other capabilities of biological systems cannot be reliably predicted at this time. Research funding that is based on the ability of investigators to produce experimental demonstrations that link to abstract models and guide long-term vision is most appropriate to achieve this goal."
TCI Co., Ltd. (Chinese: 大江生醫股份有限公司) is a Taiwanese contract development and manufacturing organization (CDMO) specializing in the research, development and production of functional beverages, dietary supplements and skincare products. Headquartered in the Neihu Technology Park in Taipei, TCI evolved from an original trading company founded in 1980 into a CDMO group serving clients across Asia, Europe and North America, and is publicly traded on Taiwan's over-the-counter market under the code 8436.
==== Photorejuvenation ==== Laser resurfacing is an FDA-cleared skin resurfacing procedure in which lasers are used to improve the condition of the skin. Two types of lasers are used to reduce the appearance of fine lines and wrinkles on the face; laser ablation, which removes thin layers of skin, and nonablative lasers that stimulate collagen production. Nonablative lasers are less effective than ablative ones, but they are less invasive, and recovery time is short. After the procedure people experience temporary redness, itching and swelling.
=== General references === Daxer, Albert; Misof, Klaus; Grabner, Barbara; Ettl, Armin; Fratzl, Peter (1998). "Collagen fibrils in the human corneal stroma: Structure and aging". Investigative Ophthalmology & Visual Science. 39 (3): 644–8. PMID 9501878. Daxer, Albert; Fratzl, Peter (1997). "Collagen fibril orientation in the human corneal stroma and its implication in keratoconus". Investigative Ophthalmology & Visual Science. 38 (1): 121–9. PMID 9008637. Fratzl, Peter; Daxer, Albert (1993). "Structural transformation of collagen fibrils in corneal stroma during drying. An x-ray scattering study". Biophysical Journal. 64 (4): 1210–4. Bibcode:1993BpJ....64.1210F. doi:10.1016/S0006-3495(93)81487-5. PMC 1262438. PMID 8494978.
Sources: en.wikipedia.org
Metabolic diseases Immunosuppression Connective tissue disorders Smoking – Smoking causes a delay in the speed of wound repair notably in the proliferative and inflammatory phases. It also increases the likelihood of certain complications such as wound rupture, wound and flap necrosis, decrease in wound tensile strength and infection. Passive smoking also impairs a proper wound healing process. Age – Increased age (over 60 years) is a risk factor for impaired wound healing. It is recognized that, in older adults of otherwise overall good health, the effects of aging causes a temporal delay in healing, but no major impairment with regard to the quality of healing. Delayed wound healing in patients of increasing age is associated with altered inflammatory response; for example delayed T-cell infiltration of the wound with alterations in the production of chemokines, and reduced macrophage phagocytic capacity. Alcohol – Alcohol consumption impairs wound healing and also increases the chances of infection. Alcohol affects the proliferative phase of healing. A single unit of alcohol causes a negative effect on re-epithelialization, wound closure, collagen production and angiogenesis. In the 2000s there arose the first Mathematical models of the healing process, based on simplified assumptions and on a system of differential equations solved through MATLAB. The models show that the "rate of the healing process" appears to be "highly influenced by the activity and size of the injury itself as well as the activity of the healing agent."
=== Second independence (2025–present) === Sumo Group was acquired by Tencent in 2022, and in early 2025, underwent a management change with a goal of focusing only on co-development work using licensed intellectual property. As part of this change, the Chinese Room had around a dozen staff downsized in June 2025. In July 2025, the Chinese Room was bought out by management with help from Hiro Capital, with studio head Ed Daly continuing to lead the company. The studio said the buyout was done to avoid being sold off by the Sumo Group to another publisher or private equity group. Daly said the buyout "allows us to scratch the creative itch of continuing to work on new, original intellectual property, but also to partner with other studios on other projects when they fit in with our vision". In February 2026, the Chinese Room announced a publishing deal with Lyrical Games for a new game.
Recent public debates in artificial intelligence have increasingly focused on its broader societal and ethical implications. It has been argued AI will become so powerful that humanity may irreversibly lose control of it. This could, as physicist Stephen Hawking stated, "spell the end of the human race". This scenario has been common in science fiction, when a computer or robot suddenly develops a human-like "self-awareness" (or "sentience" or "consciousness") and becomes a malevolent character. These sci-fi scenarios are misleading in several ways. First, AI does not require human-like sentience to be an existential risk. Modern AI programs are given specific goals and use learning and intelligence to achieve them. Philosopher Nick Bostrom argued that if one gives almost any goal to a sufficiently powerful AI, it may choose to destroy humanity to achieve it (he used the example of an automated paperclip factory that destroys the world to get more iron for paperclips). Stuart Russell gives the example of household robot that tries to find a way to kill its owner to prevent it from being unplugged, reasoning that "you can't fetch the coffee if you're dead." (These are examples of "instrumental convergence".) In order to be safe for humanity, a superintelligence would have to be genuinely aligned with humanity's morality and values so that it is "fundamentally on our side". Second, Yuval Noah Harari argues that AI does not require a robot body or physical control to pose an existential risk. The essential parts of civilisation are not physical.
=== United States (1804) === On 29 April 1804, Alexander von Humboldt, accompanied by Bonpland and Monttfar, embarked from Havana on the Spanish frigate Concepcion en route to Philadelphia. They endured a week-long storm in the Bahama Straits, raising concerns for the safety of their scientific collections. After 24 days, they reached the calm waters of Delaware, where they had their first views of the United States. The landscape featured low, forest-covered shores punctuated with marshland, and as they neared Philadelphia, attractive farmhouses came into sight amidst the forest clearings. However, upon closer approach, the waterfront revealed an unsightly scene of wooden warehouses and refuse. Behind this façade lay a well-organized city of 75,000 residents, reminiscent of European towns. Its cobblestone streets lined with poplar trees, elegant three-storey red-brick houses, and well-furnished interiors stood in stark contrast to the initial impression. The main public building, aside from the State House, was Philosophic Hall, home to the American Philosophical Society, which played a crucial role in arranging for Humboldt's visit. Despite Philadelphia losing its capital status to Washington, it remained the cultural and scientific heart of the burgeoning republic. Humboldt and his companions were accommodated in an inn near the harbor on Market Street, and their arrival was promptly covered in the local newspapers.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.